Dr. Margileth defines a triple negative breast cancer as breast cancers that have negative estrogen receptor, negative progesterone receptor and negative HER2/neu gene. He further describes treatment options and risk of recurrence. Click Here & Get The 15 Breast Cancer Questions To Ask Your Doctor http://www.breastcanceranswers.com/what-breast-cancer-questions-to-ask/# Breast Cancer Answers is a social media show where viewers submit a question and get the answer from an expert. Submit your question now at, http://www.breastcanceranswers.com/ask. *** This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk. If you have any concerns about your health, please consult with a physician.
Views: 12638 Breast Cancer Answers®
Dr Ann Pittier, radiation oncologist, explains how animal products promote breast cancer, and how a plant-based diet can help prevent breast cancer recurrence. Dr Joseph Marquez, urologist, explains how he talks to patients about their diet and the potential for a plant-based diet to prevent and treat Prostate Cancer & Erectile Dysfunction. See http://www.vegetarianprescription.org for medical studies on the use of plant-based diets to treat and prevent disease. Hosted at Seattle's Vegfest on April 1, 2017, by Vegetarians of Washington. http://www.vegofwa.org
Views: 78 Plant-Based Diets in Medicine
*DCIS Diagnosis & The Oncotype Breast Cancer Assay for DCIS* Genomic Health, Inc. reported positive results from an initial validation study of Oncotype DX® in patients suffering from a pre-invasive form of breast cancer, also known as ductal carcinoma in situ (DCIS). This is the second largest, independent clinical study of Oncotype DX. The Ontario DCIS Study Group in Canada conducted this clinical study which met its primary endpoint by substantiating that the Oncotype DX DCIS Score™ can predict the risk of local recurrence. Local recurrence indicates either the development of a new invasive breast cancer or the recurrence of DCIS in the same breast. DCIS is a stage zero breast cancer that affects 1 out of every 5 women in the U.S. The study revealed that approximately 80% of women diagnosed with DCIS currently receive unnecessary aggressive therapy, while others in need of it often miss the chance of undergoing the advance treatment. This often causes cancer to proliferate, which could have otherwise been avoided with proper treatment. However, the above-mentioned study showed that Oncotype DX can predict individual risk of recurrence and thereby help in taking suitable treatment decisions. This not only leads to timely treatment decisions but also reduces healthcare costs. The aforementioned study results represent the largest genomic study in DCIS to date. These results reaffirm the inferences of the previously-released validation study performed by the ECOG-ACRIN Cancer Research Group. This is the first time the Oncotype DX DCIS Score has succeeded in predicting the risk of local recurrence in a group of patients treated with radiation therapy in clinical practice. The study involved more than 1,200 patients diagnosed with DCIS between 1994 and 2003. Researchers from Genomic Health collaborated with the Ontario DCIS Study Group to examine the tumor samples collected from these patients. The patient group constituted both patients treated with surgery alone and those treated with surgery plus radiation. Genomic Health and the Ontario DCIS Study Group plans to submit the results from this study at the 2014 San Antonio Breast Cancer Symposium in December. Recently, a clinical decision impact study presented at the American Society of Clinical Oncology revealed that the Oncotype DX DCIS Score results have changed treatment recommendations for 1 out of 3 patients with DCIS, highlighting the need for optimizing treatment of DCIS. The Oncotype DX DCIS Score looks at 12 genes within a tumor sample to reveal the aggressiveness of the disease. Join Medical Director Dr. Jay Harness along with co-founders of BreastCancerAnswers.com Todd Hartley & Wendy Hartley as they discuss getting diagnosed with DCIS and the Oncotype DX Breast Cancer Assay for DCIS patients. The live event will take place on April 2nd at 9 am PT/12 pm ET. To watch it on your mobile device, go to http://www.youtube.com/watch?v=zLAUX2x45Hc #ODX #DCIS #BreastCancer
Views: 3920 Breast Cancer Answers®
http://www.howdini.com/howdini-video-7257883.html How to cope with fear of breast cancer recurrence Once a woman has undergone treatment for breast cancer, often her biggest concern is whether the cancer will appear in the opposite breast or spread to other areas of the body. Dr. Anne Moore, a leading breast oncologist, shares important information to help breast cancer survivors cope with the fear of recurrence.
Views: 1635 Howdini
Susan G. Komen for the Cure® Ambassador René Syler speaks with Dr. Anne Moore, Medical Director of Breast Oncology Program at the Weill Medical College of Cornell University and Attending Physician at The New York Presbyterian Hospital, about how to cope with the fear of a recurrence of breast cancer.
Views: 568 Susan G. Komen®
A study out of Singapore, published in Annals of Oncology in March of 2012, showed that breast cancer patients treated with chemotherapy had symptoms of chemobrain manifested by memory loss, difficulty in decision making and speech problems. Patients were generally not aware they had symptoms because they attributed them to fatigue, anxiety, and mood changes related to the physical side effects of chemotherapy. They were unable to fulfill their duties as mothers and wives because of their cognitive defects. Chemotherapy is overused in this country in both people with mild disease that don't really benefit much from treatment and those who are stage 4 and only respond between 2-3% of the time. It is interesting that oncologists generally don't take the same aggressive treatment themselves that they recommend to their patients. Take Dr. Saputo's Breast Cancer Health Assessment Once you have breast cancer you need to know the best strategies to slow down or reverse its growth. In Dr. Saputo's Breast Cancer Health Assessment we will ask you about the type of breast cancer you have, what treatment you've considered or completed, whether or not you're interested in CAM approaches to treatment, and important lifestyle factors that could have an impact on how your cancer will affect you. You will immediately be emailed back audios and videos Dr. Saputo believes will guide you to information that can help you manage your cancer and support the body's immune defenses. There is a lot we can do to prevent activating cancer genes and to protect us from developing breast cancer. Most breast cancers are epigenetic, not genetic! http://doctorsaputo.com/a/breast-cancer-health-assessment
Views: 238 DoctorSaputo
Reshma Jagsi, MD, DPhil, associate professor, Department of Radiation Oncology, University of Michigan Health System, discusses the benefits of hypofractionated radiotherapy for patients with breast cancer.
Views: 212 OncLiveTV
John Marshall, MD, provides insight on treatment approaches for progression of metastatic pancreatic cancers. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Views: 206 Targeted Oncology
Frankie Ann Holmes, MD, a physician at Texas Oncology, discusses neoadjuvant endocrine therapy for patients with breast cancer.
Views: 108 OncLiveTV
Renowned breast cancer expert Dr. Alice Police, surgical oncologist at UC Irvine Health Pacific Breast Care Center, discusses treating early stage breast cancer with a double mastectomy and the latest advances in breast conserving surgery. Police is joined by Dr. Freddie J. Combs, director of breast imaging at Pacific Breast Care Center, who explains what you need to know about breast cancer screening and how to determine if you’re at high risk for breast cancer. This webinar originally aired on Oct. 9, 2014 at 11 a.m. PST. #TheAntiCancer | http://www.anti-cancer.com Get patient stories, wellness tips, health care news and more on our Live Well blog: http://www.ucirvinehealth.org/blog UC Irvine Health | http://www.ucirvinehealth.org
Views: 967 UCI Health
http://www.breastcancerdiscovery.com One of the biggest concerns when being treated and operated for breast cancer is it coming back. In Day 27, Dr. Susan Boolbol, breast cancer surgeon from Beth Israel Medical Center, discusses preventive treatments you can do to avoid having your breast cancer coming back. Video Transcript: "With breast cancer, one of the things that we as physicians look at is something called hormone receptors. There are two major hormones that we look at. One is called estrogen and one is called progesterone and those are two hormones that, once we remove the cancer, its examined to see is what we call sensitive to either one of those hormones. If the cancer cells are sensitive to one or both of those hormones, you can really think of those hormones as the food chain to the cancer cells so the cancer is growing because those hormones are stimulating it to grow. Even though the cancer is removed surgically, we want to do something to decrease the risk of that breast cancer coming back. One of the possible treatments that we use is what we call hormonal and what that does is it's a pill that you take to block those hormones from getting to the breast. There are two major classes of pills used in that arena. One is what many women know of is something called Tamoxifen and that's really a drug that we use now in pre-menopausal women, young women who are still getting their periods and that is really the choice that we have for pre-menopausal women. In post menopausal women, we have many choices. We have Tamoxifen, but we also have another whole class of drugs called aromatase inhibitors. They actually have the same result in blocking these hormones from getting to the breast. They work in a different way. So they get to the same results in a different way. We know through studies that have been done that they actually have slightly better results than Tamoxifen. So when we can use those drugs we prefer to use those drugs over Tamoxifen."
Views: 451 DispellingTheMyths
STOCKHOLM -- Local recurrence in early breast cancer occurred 35% less often in women who received synchronous chemoradiation rather than sequential therapy, long-term follow-up data from a large clinical trial showed. Medpage Today: http://medpagetoday.com Online CME - Continuing medical education: http://www.medpagetoday.com/cme/ Latest medical news: http://www.medpagetoday.com/latest/ The MedPage Today app: iOS: https://goo.gl/JKrkHq Android: https://play.google.com/store/apps/details?id=com.medpagetoday.medpage MedPage Today Youtube Channel: https://www.youtube.com/user/MedPageToday Medpage Today on Facebook: https://www.facebook.com/MedPageToday
Views: 54 MedPage Today
Matteo Lambertini talks about the long term results analysis from an international study exploring the safety of pregnancy in patients with an history of ER positive breast cancer. At 10 years, no significant difference was observed in DFS or OS. Abstract as referenced in the ASCO 2017 programme: LBA 10066: Safety of pregnancy in patients with history of estrogen receptor positive breast cancer Long-term follow-up analysis from a multi center study. Produced by the European Society for Medical Oncology http://www.esmo.oncologypro.org
Views: 326 European Society for Medical Oncology
Amy, a breast cancer survivor, describes her experience using Genomic Health's Oncotype DX DCIS Breast Cancer Score to personalize her treatment options. Share this video with your loved ones to help empower other women facing a DCIS (ductal carcinoma in situ) breast cancer diagnosis to ask for personalized treatment. For more information, please visit: www.genomichealth.com www.oncotypedx.com
Views: 8828 Genomic Health, Inc.
Frankie Ann Holmes, MD, Texas Oncology, discusses challenges with neoadjuvant endocrine therapy in breast cancer.
Views: 53 Targeted Oncology
http://www.howdini.com/howdini-video-7307820.html How to recognize inflammatory breast cancer symptoms Not all breast cancer involves a lump. There is a rare, but serious form known as inflammatory breast cancer whose symptoms are unique. Dr. Anne Moore, a leading breast oncologist, describes the symptoms and treatment for inflammatory breast cancer.
Views: 43420 Howdini
Paula Klein, MD, Director of Breast Medical Oncology at the Continuum Cancer Centers of New York, tells you about the advanced treatments available for breast cancer at CCCNY. Learn more about breast cancer treatment at the CCCNY website http://www.cancerteam.com/cancer-treatment/breast-cancer-treatment
Views: 1724 Mount Sinai Beth Israel
Anne Moore, M.D., the Director of the Weill Cornell Breast Center at NewYork-Presbyterian/Weill Cornell Medical Center in New York City, discusses innovations in treatment for patients with breast cancer. You can learn more about Dr. Moore at: http://www.weillcornell.org/annemoore/index.html
Views: 4793 NewYork-Presbyterian Hospital
Envita is a leading cancer, Lyme disease, and chronic disease Unipathic treatment center in Scottsdale, Arizona. Our goal is to use the best of real time cancer and Lyme disease diagnostics to determine the best integrative cancer and Lyme disease treatments from around the world to help our patients receive a viable 2nd opinion. Upon discovering a lump in her breast and receiving a mammogram, Ashley was diagnosed with stage two breast cancer. Ashley was shocked to receive this diagnosis because of her healthy lifestyle, she began to seek out treatment. Ashley visited MD Anderson and Texas Oncology where she received the same protocol for treatment. Fearing the damage these treatments would cause to her body she began to search out an alternative. Having heard from her mother about a friend who had been treated at Envita 14 years prior and was still in remission, Ashley decided Envita was the clinic she needed to get well. She is currently in remission. ---------------------------------------------------------------------------------------------- Be sure to visit and subscribe to our channel for other informative videos: https://www.youtube.com/c/EnvitaNaturalMedicalCenterScottsdale To get a hold of a patient care coordinator today call us at: 1-866-830-4576 To receive information about a condition you may be dealing with visit https://www.envita.com/contact Visit out website to learn more: https://www.envita.com/ For cancer treatment info: https://www.envita.com/conditions/cancer For Envita's articles on cancer visit: https://www.envita.com/cancer For Lyme disease treatment info: https://www.envita.com/conditions/lyme-disease For Envita's articles on Lyme disease visit: https://www.envita.com/lyme-disease Facebook: https://www.facebook.com/Envita Twitter: https://twitter.com/envitamedical Google+: https://plus.google.com/+EnvitaNaturalMedicalCenterScottsdale Tumblr: https://envitamedicalcenters.tumblr.com/ Pinterest: https://www.pinterest.com/envitamedicalce/ Vimeo: https://vimeo.com/user10286984
Views: 16543 Envita Medical Center
Patients newly diagnosed with breast cancer face multiple challenges, both in the short-term with decision making regarding surgical options for the treatment of their cancer, and in the long-term facing the reality that they may develop metastatic disease which is presently incurable. As a breast surgical oncologist and transitional scientist, Dr. DeMore has taken two approaches to attempt to improve the quality of care for patients with breast cancer. As a surgeon, she has played an integral role in studying minimally invasive techniques that have changed the standard of care for the indicators for sentinel lymph node biopsy, as well as expanding indications for breast conservation with neoadjuvant chemotherapy, and as a co-investigator on an institutional trial of intraoperative radiation therapy for breast cancer. In an attempt to improve patient care she has been a co-investigator on 11 active clinical trials and 24 completed clinical trials, which has led to 16 publications relating to clinical advances in the care of breast cancer patients. Although she is keenly aware of the importance of advancing less invasive procedures for our patients that will ultimately improve their quality of life, she is also aware that the most devastating consequence of this disease is not how it behaves locally, but rather the pain and suffering to patients and their families when metastatic disease develops. Her goal as a physician-scientist is to develop novel therapies for the treatment and potential cure for patients with metastatic breast cancer, and she gains her inspiration from her work daily from her interaction with her patients. Her approach to developing novel therapies for breast cancer is in the field tumor angiogenesis, a field that she has been involved in for over 25 years. In 1991 she spent 3 years of dedicated research time in Dr. Judah Folkman’s laboratory at Children’s Hospital, Harvard Medical School. The time she spent in Dr. Folkman’s laboratory was her inspiration for pursuing bench-to bedside research in tumor angiogenesis and for developing a career in breast cancer research. After completing surgical oncology fellowship at Memorial Sloan-Kettering Cancer Center, Dr. DeMore came to UNC in 2001 and started her lab. The focus of her lab has been on discovering novel factors that stimulate blood vessel growth to tumors, and to develop new drugs that block these factors and therefore inhibit tumor growth. From a clinical perspective her goal is to continue to be actively engaged in patient care as a breast surgeon and continue to develop and accrue patients onto clinical trials. Dr. DeMore is interested in ensuring high quality clinically relevant grants are funded through the NIH and has been appointed to a 6 year term on the NIH Oncology 2, Translational Clinical IRG, Cancer Immunopathology and Immunotherapy Study Section. Her hope is that over the next twenty years she will have helped contribute to excellent patient care, advancement of less invasive survival techniques, and development of novel therapies that will improve survival for patients with metastatic disease. ➨ Visit Dr. DeMore's profile page http://www.muschealth.org/providerdirectory/DeMore-Nancy ➨ Follow MUSC Health on Twitter https://twitter.com/muschealth ➨ Like MUSC Health on Facebook http://www.facebook.com/MUSChealth ➨ Subscribe to the MUSC Health Blog http://www.muschealth.com/blog/ ➨ Request an appointment by calling MUSC Health at 843-792-1414.
Views: 647 MUSC Health
At the American Society of Clinical Oncology (ASCO) 2012, Elizabeth Ann Mittendorf, MD, MD Anderson, discusses breast cancer and AE-37.
Views: 1074 Oncology.TV
At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Giuseppe Viale (European Institute of Oncology and University of Milan, Milan, Italy) discusses personalised genomic medicine for breast cancer, including the challenges of designing meaningful clinical trials to identify novel and relevant genetic disease biomarkers and the requirement for collaboration by multidisciplinary teams.
Views: 137 European Medical Group
Hyman B. Muss, MD, School of Medicine, University of North Carolina (UNC)-Chapel Hill, Breast Cancer, Geriatric Oncology Program, Mary Jones Hudson Distinguished Professorship in Geriatric Oncology, discusses assessing treatment response in patients with metastatic breast cancer.
Views: 50 OncLiveTV
The QVC and FFANY Shoes on Sale event directly benefits breast cancer research at the University of Michigan Comprehensive Cancer Center.
Views: 309 Michigan Medicine
Sramila Aithal, MD, medical oncologist, Cancer Treatment Centers of America, Eastern Regional Medical Center, speaks about the use of the AE37 peptide vaccine in breast cancer. The AE37 peptide vaccine is an immune stimulant that recognizes HER2/neu protein in breast cancer as foreign. The vaccine was studied in a phase II trial and the results were positive. After a 22-month follow up of a phase II trial, there was a 43% risk reduction in the vaccine arm. Aithal says that while the vaccine showed promising results in early stage breast cancer and reduced the risk of recurrence, it needs additional phase III studies before being clinically implemented. For more resources visit: http://targetedhc.com/
Views: 477 Targeted Oncology
In this episode of Ancient Medicine Today, Jordan Rubin and Dr. Leigh Erin Connealy talk about the part your heart and mind play in how you combat cancer — and other health issues. *This content is strictly the opinion of Jordan Rubin, and is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of medical advice or treatment from a personal physician. All viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. Neither Dr. Axe nor the publisher of this content takes responsibility for possible health consequences of any person or persons reading or following the information in this educational content. All viewers of this content, especially those taking prescription or over-the-counter medications, should consult their physicians before beginning any nutrition, supplement or lifestyle program.
Views: 31082 Dr. Josh Axe
Cheryl Buck’s uterine cancer survivor story really began before she was ever diagnosed with uterine cancer. In 2007, she was reading a book about a 16-year-old boy who had cancer. She didn’t know it at the time but the story would soon hit home. In the book, she was intrigued by the mention of a Dr. Max Gerson, whose specialty was treating cancer naturally. Right then, she decided that if she ever got cancer, she would follow his advice. Fast forward a year; Cheryl had an ultrasound on her body and was told she had a lesion on her breast. She knew right then and there she would use the methods she learned from Dr. Gerson. She went to an underground Gerson clinic in CA and learned the Gerson therapy protocol. After returning home she followed it for a period of time, and felt better than she ever had. However she eventually stopped. Seven years later Cheryl noticed that she was spotting. She found a gynecologist and that’s when she learned she had uterine cancer. Like so many, her doctor wanted her to rush her into surgery, radiation, and chemotherapy. Not wanting to go that route, Cheryl searched for more information on alternative cancer treatments and a holistic health doctor for uterine cancer. She found Dr. Vickers who specializes in alternative medicine for cancer and decided to go to his clinic in Mexico. By using his alternative uterine cancer treatments, doing the Gerson protocol, and other therapies she learned about while watching The Truth About Cancer, Cheryl feels better than she has in years. There are ways for healing uterine cancer naturally and to see how Cheryl did it, check out the video above and listen to her inspiring story of recovery. If you like this video, please give it a thumbs up and share it with others you love and care about. And don't forget to SUBSCRIBE to our channel to not miss any new uploads. ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Have you survived a cancer diagnosis and lived to tell about it? We hear so many amazing stories from our readers about how they beat cancer using the very techniques they’ve learned from The Truth About Cancer… and we’d love to hear YOUR story! Sharing these stories brings hope to those who have been diagnosed with or are currently dealing with cancer. So, if you have a personal story to share of your triumph over cancer, please follow this link and tell us all about it: http://bit.ly/your-cancer-survivor-story-yt WATCH MORE INCREDIBLE CANCER SURVIVOR STORIES: http://bit.ly/cancer-survivor-story-yt ----------------------------------------------------------------------------------------------------------- Visit our website: http://bit.ly/official-website-ttac-yt Join TTAC's 1 million FB fans: http://bit.ly/TTAC-Facebook-YT Follow us on PINTEREST: http://bit.ly/TTAC-Pinterest-YT Find us on INSTAGRAM: http://bit.ly/TTAC-Instagram-YT -------------------------------------------------- About The Truth About Cancer -------------------------------------------------- The Truth About Cancer’s mission is to inform, educate, and eradicate the pandemic of cancer in our modern world. Every single day, tens of thousands of people just like you are curing cancer (and/or preventing it) from destroying their bodies. It’s time to take matters into your own hands and educate yourself on real cancer prevention and treatments. It could save your life or the life of someone you love. --------------------------------------- About Ty Bollinger --------------------------------------- Ty Bollinger is a devoted husband, father, a best-selling author, and a Christian. He is also a licensed CPA, health freedom advocate, cancer researcher, former competitive bodybuilder, and author of the best-selling book Cancer - Step Outside the Box, which has sold over 100,000 copies worldwide. After losing his mother and father and several family members to cancer, Ty’s heartbreak and grief coupled with his firm belief that chemotherapy, radiation, and surgery were the NOT the most effective treatments available for cancer patients led him on a path of discovery. He began a quest to learn everything he possibly could about alternative cancer treatments and the medical industry. What he uncovered was shocking. On his journey, he’s interviewed cutting-edge scientists, leading alternative doctors, and groundbreaking researchers to learn about hidden alternative cancer treatments. What he uncovered help to create The Truth About Cancer and its 3 awe-inspiring docuseries: The Quest for The Cures, The Quest For The Cures Continues, and The Truth About Cancer: A Global Quest. Ty has touched the hearts and changed the lives of thousands of people around the world. Ty speaks frequently at conferences, local health group meetings, churches, and guest stars on multiple radio and TV shows and writes for numerous magazines and websites. -----------------------------------------------------------------------------------------------------------
Views: 6395 The Truth About Cancer
Elizabeth Mittendorf, MD, PhD, associate professor, Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, discusses an upcoming peptide vaccine to prevent recurrence in patients with breast cancer. Mittendorf says initially there was the HER2 peptide nelipepimut-S (E75) vaccine (NeuVax) that proved to be immunogenic. She says in a recent study, her and her colleagues combined E75 with GMCSF to help prevent recurrence. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Views: 668 Targeted Oncology
Moderator, Debu Tripathy, MD, introduces the panel for a unique discussion that features peer-to-peer expert exchange, authoritative insights, opinions, and perspectives on important issues facing today's cancer care professionals. The expert panel includes: William J. Gradishar, MD, Joyce A. O'Shaughnessy, MD, Christy A. Russell, MD, and Linda T. Vahdat, MD. In this section, the panel discusses the current role of HER2 agents in the treatment of early stage breast cancer, particularly the management of T1N0 breast cancer. For more on this discussion, visit http://www.onclive.com/peer-exchange/early-breast-cancer
Views: 1075 OncLiveTV
http://www.beetmedicine.tv/2009/06/about-clinical-trials-for-breast-cancer.html The goal of clinical trials is to improve the outcome of standard therapy, to determine if a new approach will work better as well as to monitor side effects. These do take more time and there are often more tests, but, the benefit is that the treatments may prove to be better and frequently more personalized. Interviewees: Hope S. Rugo, MD, Clinical Professor of Medicine; Director, Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center Hope Rugo Michael Alvarado, MD, Asst. Prof. in Residence, Surgery, Carol Franc Buck Breast Care Center, UCSF Helen Diller Family Comprehensive Cancer Center Michael Alvarado
Views: 380 BeetMedicineTV
An investigational genetic test may not only be able to differentiate women likely to have early recurrence of estrogen receptor-positive breast cancer, but also could lead to novel combinations of existing drugs to treat these patients earlier in the disease process, according to Dr. Minetta C. Liu. See the related story at http://tinyurl.com/dy5d6sm
Views: 240 MDedge
Tammy Young, MD, is an oncologist with Jackson Oncology Associates and affiliated with Baptist Cancer Services in Jackson, Miss. She appeared on the WLBT show in October of 2010 to talk about the survival rates of breast cancer.
Views: 402 BaptistMedNews
Read the Transcript: http://to.pbs.org/inoS0J Two studies have doctors energized about the prospects for treating people with advanced cases of the deadly skin cancer and the prospects for a new breast cancer drug. Judy Woodruff discusses the latest developments with Dr. George Sledge of The American Society of Clinical Oncology.
Views: 783 PBS NewsHour
By: Erin Nichols -- Millions of American women are diagnosed with breast cancer every year, but now there's new hope for survival thanks to a medical breakthrough that's revolutionizing the way patients are treated. I was diagnosed almost to the day one year ago, said Corina Uribe. Uribe never imagined she would be diagnosed with breast cancer. I went to my scheduled mammogram and within the hour I was having the biopsy done, she said. Uribe went to see Dr. Jayasree Rao at Oncology San Antonio. Dr. Rao introduced her to a new group of tests called the Blueprint molecular test and the Mammaprint test, which allowed Dr. Rao to customize her treatment. Thankfully it was determined I did not need chemotherapy as part of my treatment, Uribe said. I'm very grateful. When I meet a patient I tell them not all breast cancers are the same and we are going to find the best care based on everything included the tumors specificity, said Dr. Rao. The tests work like this: doctors take a sample of a breast tumor, similar to a biopsy. Next, the sample is tested on a molecular level. Doctors can then use the tumor's own cellular make-up to determine what the next step in treatment will be. Even before the surgery, the doctor was able to see if these patients needed chemotherapy or not, and gave them the ability to categorize differently, said Dr. Rao. Depending on the results, Dr. Rao says patients may not even need a mastectomy. If there's one cancer we have made large strides it's breast cancer, and I think it's made large strides for other cancers to follow that, said Dr. Rao. Dr. Rao hopes the tests become part of the standard treatment for breast cancer care. Uribe says shes breast cancer free. It's a wonderful Christmas present, Uribe said. I couldn't ask for anything else. The tests will be presented at the San Antonio Breast Cancer Symposium next week. If you've been recently diagnosed with breast cancer and are interested in learning more about the test talk, to your oncologist.
Views: 270 FOX San Antonio
From ASCO 2014, Elizabeth A. Mittendorf, M.D., Ph.D., an Assistant Professor in the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center discusses the primary analysis of the prospective, randomized, single-blinded phase II trial of AE37 vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients.
Views: 1280 GenerexBiotechnology
Exercise and rehabilitation play an important role in helping patients cope with treatment and its side-effects, and recover health. Moreover, for some types of cancer, exercise has been shown to reduce the risk of recurrence.
Views: 1793 WellspringCancer
Dr. Wendy Chen, medical oncologist with the Breast Oncology Program, discusses her work, why she welcomes family member participation in medical appointments, and the importance of individualized treatment plans. Learn more about how Dana-Farber's physicians treat breast cancer at http://www.dana-farber.org/Adult-Care/Treatment-and-Support/Treatment-Centers-and-Clinical-Services/Breast-Cancer-Treatment-Center.aspx.
Views: 2061 Dana-Farber Cancer Institute
Andrew D. Seidman, MD, attending physician, Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, discusses the shift paradigm of breast cancer treatment and the development of targeted agents that disrupt certain pathways. Seidman says historically treatment and management of breast cancer has been accomplished with chemotherapy, endocrine therapy and HER2-targeted therapy. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Views: 104 Targeted Oncology
In this video, Vandana Abramson, MD, assistant professor of medicine, Division of Hematology/Oncology, Vanderbilt University, Nashville, TN, discusses the various strategies utilized in the treatment of metastatic breast cancer. Dr Abramson says that they are looking at new mutations within the subgroups, specifically PI3 kinase mutations, as targets for estrogen receptor positive breast cancer. For HER-2 positive breast cancer there are many new therapies such as, Kadcyla, Pertuzumab, Trastuzumab and more. "That's where I really think breast cancer is headed, said Dr Abramson. "We are figuring out how we can target specific subtypes in a better way." This video was taken on May 2, 2013, at the NAMCP Spring Managed Care Forum in Orlando, FL.
Views: 745 AJMCtv
Dr. Vera Kneer, Germany Landau, Germany Introduction: The present article describes the ongoing partial remission of a 44 year old patient with originally ER/PR positive HER2+negative metastatic breast cancer (local recurrence, bones, lymph nodes, pleural carcinosis) with excellent response to an individual integrative therapy consisting of metronomic chemotherapy with Capecitabine, Arcoxia and Cimetidine together with loco regional hyperthermia, multitargeting phytochemicals like curcumin, green tea, milk thistle, graviola, artemisinin, enzymes, D3, selenium, amino acids, infusions with vit C 15 g as well as gluthatione. To treat severe pain and loss of appetite she received THC oil. Helleborus niger was used in form of daily inhalations to treat symptomatic dyspnea and dry coughs in pleural effusion. Moreover Helleborus niger was administered s.c. for immunstimulation and for diuretic purpose. Integrative Medicine Meeting - IMM 2016 Rosenfeld, Germany 20 September, 2016
At the ASCO 2013 Meeting, Elizabeth A. Mittendorf, M.D., Ph.D., an Assistant Professor in the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center discusses the effect of immunization with Ii-key modified HER2 (776-790) peptide vaccine (AE37) on immunologic responses in breast cancer patients.
Views: 738 Oncology.TV
Presented by Jean Harvey, PhD, RD at the Vermont Cancer Center's 16th Annual Breast Cancer Conference (October 4, 2013). For more information about the Breast Cancer Conference, visit http://www.uvm.edu/medicine/vtbreastcancerconference.
Views: 1409 The University of Vermont Cancer Center
Tow truck driver by day, cancer survivor Faith is truly tougher than cancer. She has survived breast cancer, ovarian cancer and cervical cancer. And in between her battles with cancer, she still managed to run two businesses. Visit http://www.oacancer.com/breast-cancer-survivor-story-faith/ to read more about her story. #BreastCancerSurvivor #BreastCancerAwareness #BreastCancer
Views: 358 Oncology Associates
Robert L. Fine, MD, associate professor of medicine, Herbert Irving, director, Experimental Therapeutics, medical oncology director, Pancreas Center, Columbia University, discusses reducing the risk of relapse in patients with pancreatic cancer. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Views: 158 Targeted Oncology
Wellesley residents Melody Tortosa and Fran Hogan are both breast cancer survivors. They share their breast cancer journeys with WCMP-TV Wellesley and discuss their breast cancer diagnosis, treatment, recovery, HopeWalks experience, and community involvement. Both women were diagnosed at Newton-Wellesley Hospital and Melody received her treatment from the hospital's Vernon Cancer Center. http://www.nwh.org/cancer WCMP-TV, Winter 2011
Views: 907 Newton-Wellesley Hospital